Acipimox
Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1][2][3].
Product Specifications
CAS Number
51037-30-0
Product Name Alternative
K-9321
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Carbonic Anhydrase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/Acipimox.html
Purity
99.58
Solubility
DMSO : ≥ 100 mg/mL|H2O : 20 mg/mL (ultrasonic)
Smiles
O=C(C1=C[N+]([O-])=C(C)C=N1)O
Molecular Formula
C6H6N2O3
Molecular Weight
154.13
Precautions
H302, H315, H319, H335
References & Citations
[1]Vestergaard ET, et, al. Short-term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec;83 (12) :2671-2677.|[2]Wang-Fisher YL, et, al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174 (2) :267-72.|[3]Ahrén B. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171 (2) :161-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RR204741L3V 200 µL
Foxp4 (NM_001108788) Rat Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details 